FDA Adds Black Box to Genentech, Inc. Asthma Drug Xolair

WASHINGTON, July 2 (Reuters) - U.S. regulators on Monday finalized a strong new label warning patients and doctors about a potentially deadly allergic reaction from Genentech Inc.'s (DNA.N: Quote, Profile, Research) asthma drug Xolair.